Albumin Dosing for Hepatorenal Syndrome and Large-Volume Paracentesis
For large-volume paracentesis (>5 L), administer 6-8 g of albumin per liter of ascites removed; for hepatorenal syndrome, give 1 g/kg on day 1 (up to 100 g) followed by 20-40 g daily in combination with vasoconstrictors.
Large-Volume Paracentesis
The most recent AASLD guidance establishes clear dosing parameters 1. Albumin should be administered at 6-8 g per liter of ascites removed when more than 5 L is drained 1. This translates to approximately 40 g after 5 L removal and 64 g after 8 L removal 1. The 2024 AGA expert review reinforces that albumin is indicated for paracentesis volumes exceeding 5 L 2.
Key Dosing Considerations:
- Paracentesis ≤5 L: Albumin may not be required as smaller volumes don't cause significant hemodynamic changes 1
- Paracentesis >5 L: 6-8 g/L of ascites removed 1
- Paracentesis >8 L: Risk of postparacentesis circulatory dysfunction (PPCD) increases; consider limiting single-session volume 1
- Patients with ACLF: Use 6-8 g/L regardless of volume removed 2
Recent evidence suggests lower doses (4-6 g/L) may be adequate 3, 4, 5, but the established guideline recommendation of 6-8 g/L remains the standard of care 1. A 2026 systematic review found no significant difference between low-dose and standard-dose regimens for PPCD or renal dysfunction 5, but the evidence quality is limited by small sample sizes and heterogeneous methodology.
Administration Timing and Rate:
Albumin should be infused at the time of paracentesis 2, 1. For hypoproteinemic patients with normal blood volumes, infusion rate should not exceed 2 mL/min to avoid circulatory overload and pulmonary edema 6.
Hepatorenal Syndrome (HRS-AKI)
Albumin is an indispensable component of HRS treatment and must be combined with vasoconstrictors (typically terlipressin, or midodrine/octreotide in the US) 7, 8, 9.
Standard HRS Dosing Protocol:
- Day 1: 1 g/kg body weight (maximum ~100 g) 7
- Subsequent days: 20-40 g daily 7
- Duration: Continue until HRS reversal or up to 15 days 7
The combination of terlipressin and albumin achieves HRS reversal in approximately 43.5% of patients compared to 8.7% with albumin alone 7. A dose-response meta-analysis demonstrates that higher cumulative albumin doses correlate with improved survival: each 100 g increment in cumulative dose increases survival (HR 1.15,95% CI 1.02-1.31) 8. Expected 30-day survival rates are 43% with 200 g cumulative dose, 51% with 400 g, and 59% with 600 g 8.
Important Caveats:
Albumin alone is insufficient for HRS treatment—vasoconstrictors are essential 7, 9. The independent effect of albumin remains incompletely defined, as most evidence evaluates combination therapy 9.
Recent data suggest that doses exceeding 50 g/day in severe HRS-AKI with infection do not increase adverse outcomes, including respiratory failure 10. Concerns about fluid overload should not prevent adequate albumin dosing in appropriately selected patients 10.
Practical Algorithm:
For Large-Volume Paracentesis:
- Measure volume drained
- If >5 L: Calculate 6-8 g albumin × liters removed
- Administer IV albumin during or immediately after procedure
- Monitor for fluid overload (rare but possible) 2
For Hepatorenal Syndrome:
- Confirm HRS-AKI diagnosis (exclude other AKI causes)
- Day 1: Give 1 g/kg albumin (up to 100 g) + initiate vasoconstrictor
- Days 2-15: Give 20-40 g albumin daily + continue vasoconstrictor
- Monitor serum creatinine every 2-3 days
- Continue until HRS reversal (creatinine ≤1.5 mg/dL) or 15 days maximum 7
Adverse Effects:
Albumin-related complications are uncommon but include fluid overload, pulmonary edema, hypotension/tachycardia, and rarely rigors or pyrexia 2. The risk of respiratory failure from albumin is substantially lower than previously feared, even with high doses (>50 g/day), when used appropriately 10. Monitor hemodynamic status and avoid rapid infusion rates in patients with baseline volume overload 6.